{"prompt": "['2017N323364_01', 'CONFIDENTIAL', '2019N398531_0', '207626', '3.3.1.', 'Risk Assessment', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'Investigational Product (IP) GSK2834425 (FF/UMEC/VI), GSK573719 (UMEC), GW642444 (vilanterol), GW685698 (fluticasone furoate)', 'Pneumonia in participants with COPD', 'Pneumonia is a class concern for any ICS-', '- Participants will be informed of the risk in', 'containing product for the treatment of', 'the informed consent.', 'COPD.', '- Investigators are informed of the risk in', 'the IB', 'In a study (CTT116853) in 1810', '- Investigators will be instructed to remain', 'randomised COPD participants treated with', 'vigilant for the possible development of', 'FF/UMEC/VI or budesonide/formoterol', 'pneumonia in participants with COPD as the', '(BUD/FOR) for up to 24 weeks (Intent-To-', 'clinical features of such infections overlap', 'Treat [ITT] Population), or up to 52 weeks', 'with the symptoms of COPD exacerbations.', '(subset of 430 participants; EXT', 'For suspected cases of pneumonia,', 'Population), the incidence of events in the', 'investigators will be encouraged to arrange', 'pneumonia AEs of special interest (AESI)', 'a chest x-ray within 48 hours of diagnosis', 'group was 2.2% and 0.8 % for', '(Section 12.5.2) and to treat appropriately.', 'FF/UMEC/VI and BUD/FOR, respectively', '- Appropriate exclusion criteria as specified', 'in the ITT Population, and 1.9% and 1.8 %', 'in Section 6.2 of the protocol i.e', 'for FF/UMEC/VI and BUD/FOR,', '- Instream review of blinded AE/SAE', 'respectively, in the EXT Population. There', 'reports.', 'was one fatal case of pneumonia in a', '- All diagnoses of pneumonia', 'participant who received FF/UMEC/VI.', '(radiographically confirmed or', 'unconfirmed) must be reported as an AE or', 'The incidence of pneumonia with', 'SAE (if applicable) as specified in Section', 'FF/UMEC/VI in this study was in line with', '9.2.7.', 'the incidence of pneumonia seen in 24 week', '- Chest X-ray read required at baseline and', 'studies with F/VI (<1-2% with FF/VI', 'whenever a participant has suspected', '100/25) and less than that observed in 52', 'pneumonia or mod/severe exacerbations', 'week exacerbations studies with FF/VI (6 %', 'during the study.', '24']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_0', '207626', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'with FF/VI 100/25) [Dransfield, 2013].', 'Similarly, the incidence of pneumonia with', 'FF/UMEC/VI was less than that observed in', 'a 12 month exacerbation trial with', 'BUD/FOR (6.4%) [Sharafkhaneh, 2012].', 'Prior studies with FF/VI have demonstrated', 'risk factors associated with a higher risk of', 'pneumonia in participants with COPD (e.g.,', 'advanced age, poor lung function, low body', 'mass index (BMI), current smoking, and a', 'prior history of pneumonia) [Crim, 2009].', 'These risk factors were present in some', 'participants with pneumonia in study', 'CTT116853 with FF/UMEC/VI; however,', 'the low number of pneumonia events', 'reported in this study precludes drawing any', 'definite conclusions about risk factors.', 'These risk factors should be taken into', 'consideration when using an ICS in', 'participants with COPD. Pneumonia risk', 'will be important in the benefit-risk', 'assessment for FF/UMEC/VI in COPD', 'participants, hence a robust risk mitigation', 'strategy is being proposed.', 'Pharmacovigilance Risk Assessment', 'Committee (PRAC) recently conducted an', 'Article 31 review to evaluate the risk of', 'pneumonia with use of ICS in participants', '25']\n\n###\n\n", "completion": "END"}